The AIM-listed firm said the research deal will see both groups assess monoclonal antibodies (mAbs) targeting tumour-associated glycans (TaGs), including those that have been enhanced by the AvidiMab platform.
The US firm will conduct preclinical studies to evaluate the potential for the anti-TaG mAbs developed by AvidiMab to treat cancer.
"This continued momentum with AvidiMab and our tumour-associated glycan antibodies demonstrates the growing excitement around this platform”, said Scancell chief executive Cliff Holloway.
“This is another important collaboration for Scancell and illustrates the future value that this third platform could potentially generate for the company", he added.
The news sent the shares surging 7.9% to 6.7p in early deals.